Core Insights - Zai Lab Limited announced a late-breaking abstract featuring new data from its global Phase 1 clinical trial evaluating zocilurtatug pelitecan (zoci), previously known as ZL-1310 [1] - The abstract has been selected for an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, Massachusetts [1] Company Summary - Zai Lab Limited is actively involved in clinical trials for zocilurtatug pelitecan, indicating ongoing research and development efforts in the oncology sector [1] - The selection of the abstract for oral presentation highlights the significance of the trial results and the company's commitment to advancing cancer therapeutics [1]